辛伐他汀对高脂血症性脂肪肝治疗的实验研究

An experimental study on treating hyperlipidemic fatty liver with simvastatin

目的 探讨调脂药辛伐他汀对高脂血症性脂肪肝的作用。方法 通过高脂食饵饲养制备大鼠高脂血症性脂肪肝模型 ,分别检测模型组 (n =10 )和对照组 (n =10 )的肝指数 (肝重 /体重 )、肝功能、血脂、肝脂、血清、肝组织丙二醛 (MDA)含量及肝组织学改变。模型组剩余 2 0只大鼠随机分为两组 ,治疗组给予辛伐他汀 4mg/kg灌胃 ,每日 1次 ,4周后检测上述指标 ,并与未治疗组比较分析。 结果 高脂血症性脂肪肝模型肝指数、血脂、肝脂、血清及肝组织MDA含量显著升高 (P均 <0 .0 1) ,血脂与血清MDA含量呈正相关 (P <0 .0 1)。肝组织学呈轻、中度脂肪变 ,以小泡性脂滴为主 ;辛伐他汀治疗组血脂、肝脂、血清MDA含量显著降低 (P均 <0 .0 1) ,肝组织MDA含量降低 (P <0 .0 5 ) ,肝组织学接近正常。未治疗组肝脂有所降低 ,肝组织学有改善 ,但血脂增高持续存在。结论 辛伐他汀可安全、有效地用于高脂血症性脂肪肝的治疗。

Objective To explore the effects of simvastatin in the treatment of hyperlipidemia fatty liver. Methods Animal models were set up by feeding high caloric diet. Liver index (liver weight/body weight), liver function, blood lipid, liver lipid, the content of MDA in serum and liver were assayed before and after therapy with simvastatin. Results Liver index, blood lipid, liver lipid, and the content of MDA in liver as well as in serum increased significantly ( P <0.01). Blood lipid was correlative with the level of MDA in serum ( P < 0.01 ). Liver histology expressed mild to moderate fatty denaturation, which was mainly small fatty droplets. After being treated with simvastatin for four weeks, blood lipid, liver lipid and the content of MDA in serum decreased significantly ( P < 0.01), and the content of MDA in liver also decreased significantly ( P <0.05), and meanwhile liver histology was closed to normal. In non therapy group, hyperlipidemia persisted, although liver lipid somewhat decreased and liver histology improved.Conclusions Simvastatin is effective in the treatment of hyperlipidemia induced fatty liver.